Share GeoVax Secures Exclusive License for Gedeptin® + Immune Checkpoint Inhibitor Combination Technology Feb. 18, 2026 9:00 AM ET Source: GeoVax, Inc. Stock Quote More Company News GeoVax Announces Oncology Advisory Board to Advance Gedeptin® Development Across Solid Tumors GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
